Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis

doi:10.5306/wjco.v16.i8.106873

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 8

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (48)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-4) series, Tables (1-2) series.

Item

Count

PDF

HTML

Figures (1-4)

Tables (1-2)

Sum=46

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

Sum=0

Aug 24, 2025 (publication date) through Aug 20, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Meta-Analysis

World J Clin Oncol. Aug 24, 2025; 16(8): 106873
Published online Aug 24, 2025. doi: 10.5306/wjco.v16.i8.106873

Full Size Figure Download Figure

Figure 3 Forest plot of the meta-analysis for survival outcomes in microsatellite stable/mismatch repair-proficient population. A: Progression-free survival; B: Overall survival. HR: Hazard ratio; CI: Confidence interval; SOC: Standard-of-care; PD-1/L1: Programmed death 1 or its ligand.

Citation: Zheng T, Li XX, Zhou L, Jin JJ. Adding programmed death 1/programmed death ligand 1 inhibitors to first-line standard-of-care therapy for metastatic colorectal cancer: A meta-analysis. World J Clin Oncol 2025; 16(8): 106873
URL: https://www.wjgnet.com/2218-4333/full/v16/i8/106873.htm
DOI: https://dx.doi.org/10.5306/wjco.v16.i8.106873